SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 2
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177182.
  • 3
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707712.
  • 4
    Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990; 8: 103112.
  • 5
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 16731684.
  • 6
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 16591672.
  • 7
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809820.
  • 8
    Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat. 2005; 94: S5.
  • 9
    Perez EA, Suman VJ, Davidson NE, et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial [abstract]. Proc Am Soc Clin Oncol. 2005; 23: 17s.
  • 10
    Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23: 78117819.
  • 11
    Perez EA, Suman VJ, Davidson NE, et al. Exploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy [abstract]? Breast Cancer Res Treat. 2005; 94: S96.
  • 12
    Kurian AW, Newton Thompson R, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007; 25: 634641.
  • 13
    Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007; 25: 625633.
  • 14
    Norum J. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opin Pharmacother. 2006; 7: 16171625.
  • 15
    Ragaz J, Spinelli JJ. Cost-benefit estimates of adjuvant trastuzumab for early breast cancer [abstract]. Breast Cancer Res Treat. 2005; 94: S93.
  • 16
    Hillner B. Clinical and cost-effectiveness implications of adjuvant trastuzumab in HER2-positive breast cancer trials [abstract]. Breast Cancer Res Treat. 2005; 94: S219.
  • 17
    Norum J, Olsen JA. Trastuzumab in adjuvant breast cancer: A model based cost-effectiveness analysis [abstract]. Proc Am Soc Clin Oncol. 2006; 24: 34s.
  • 18
    Wilson E, Crown J, Ballot J, McDonnell D, Shahan E, Healy J. Estimating the real cost of adjuvant trastuzumab in patients with HER2-positive early stage breast cancer [abstract]. Proc Am Soc Clin Oncol. 2006; 24: 320s.
  • 19
    Neyt M, Albrecht J, Cocquyt V. An economic evaluation of Herceptin in adjuvant setting: The Breast Cancer International Research Group 006 trial. Ann Oncol. 2006; 17: 381390.
  • 20
    Danish National Board of Health. Trastuzumab (Herceptin) as adjuvant treatment of early breast cancer after surgical treatment. Preliminary report. Health Technology Assessment of Cancer Drugs 1: Available at: http://www.sundhedsstyrelsen.dk/upload/planlaegning_og_behandling/cemtv/mtv_af_nye_kr%C3%A6ftl%C3%A6gemidler/herceptin_en/herceptin_en.pdf, 2005.
  • 21
    National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. Available at: http://www.nice.org.uk/TA107, 2006.
  • 22
    Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol. 2005; 23: 78207826.
  • 23
    Centers for Medicare and Medicaid. Available at: http://www.cms.hhs.gov/, 2006.
  • 24
    Analysource Online. Available at: http://www.analysource.com, 2006.
  • 25
    Rao S, Kubisiak J, Gilden D: Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004; 83: 2532.
  • 26
    Oestreicher N, Ramsey SD, Linden HM, et al. Gene expression profiling and breast cancer care: What are the potential benefits and policy implications? Genet Med. 2005; 7: 380389.
  • 27
    Hornberger J, Kerrigan M, Foutel V. Cost-effectiveness of trastuzumab (Herceptin) for treatment of metastatic breast cancer [abstract]. Ann Oncol. 2002; 13: 52.
  • 28
    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 16871717.
  • 29
    Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004; 22: 854863.
  • 30
    Romond EH, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER2-positive operable breast cancer: Combined analysis of NSABP B-31 and NCCTG N9831. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 2005.
  • 31
    US Department of Labor: US Bureau of Labor Statistics. Available at: http://www.bls.gov/ [accessed February 15, 2006].
  • 32
    United States Department of the Treasury: Internal Revenue Service. Available at: http://www.irs.gov/, [accessed December 15, 2005].
  • 33
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276: 13391341.
  • 34
    Gold M. Panel on cost-effectiveness in health and medicine. Med Care. 1996; 34: DS197DS199.
  • 35
    Arias E. United States life tables, 2002. Natl Vital Stat Rep. 2004; 53: 138.
  • 36
    Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer. 2005; 104: 20542062.
  • 37
    Noe LL, Becker RV,III, Gradishar WJ, Gore M, Trotter JP. The cost effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care. 1999; 5: S389S406.
  • 38
    Delea TE, Karnon J, Smith RE. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care. 2006; 12: 374386.
  • 39
    Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer. 2004; 101: 13111322.
  • 40
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783792.
  • 41
    Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20: 12151221.
  • 42
    Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005; 23: 29002902.
  • 43
    Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006; 4( suppl 3): S1S22.
  • 44
    Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol. 2006; 24: 30323038.
  • 45
    Reddy JC, Reimann JD, Anderson SM, Klein PM. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 2006; 7: 153157.